# US 2023/0140994 A1 · Replication-deficient avian adenoviral vectors, their design and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0140994 A1
- Document ID: US20230140994A1
- Status: Published application
- Kind: A1
- Application number: 17/907,574
- Filed: 2021-03-29
- Published: 2023-05-11
- Earliest claimed: 2020-03-29
- Assignees: Greffex, Inc.
- Applicants: Greffex, Inc.
- Inventors: Uwe D. STAERZ
- Web page: https://patentgrep.com/patent/US20230140994A1

## CPC

- A61P 31/12: Antivirals
- C12N 15/861: Adenoviral vectors
- C12N 15/86: Viral vectors
- C12N 2710/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10243: viral genome or elements thereof as genetic vector
- C12N 2710/10252: relating to complementing cells and packaging systems for producing virus or viral particles
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The embodiments disclosed herein relate to the design, engineering and production of replication-deficient gene delivery vectors that are based on aviadenoviruses. More particularly their use is described in the transfer of genes, genetic engineering of cells and animals, the expression of proteins the development of vaccines. In some embodiment, the designs and packaging of partially deleted aviadenovirus vectors are disclosed. In other embodiments, the designs and packaging of fully deleted aviadenovirus vectors, the propagation of replication-deficient aviadenovirus vectors, and the characteristic and engineering of host cells are disclosed. In other embodiments, the use of such vectors in veterinary medicine is described.

## Claims

### Claim 1

An aviadenoviral gene transfer vector comprising a deleted avidenoviral genome wherein the aviadenoviral vector is replication deficient and has a partial deletion of its genome.

### Claim 2 (depends on 1)

The aviadenoviral gene transfer vector of claim 1, wherein the aviadenoviral vector is derived from one of the different species and serotypes identified as aviadenoviruses.

### Claim 3 (depends on 1)

The avidenoviral gene transfer vector of claim 1, wherein the aviadenoviral vector is derived from the Fowl Aviadenovirus A, the Falcon Aviadenovirus A, the Quail Bronchitis Virus, the Egg Drop Syndrome virus, the hemorrhagic Enteritis virus, the Marble Spleen Disease Virus and the Inclusion Body Hepatitis Virus.

### Claim 4 (depends on 3)

The aviadenoviral gene transfer vector of claim 3, wherein the avidenoviral genome is functionally deleted of open reading frames corresponding to the E1A and E1B regions.

### Claim 5 (depends on 1)

The aviadenoviral gene transfer vector of claim 1, wherein the aviadenoviral vector is derived the chicken the embryo lethal orphan (CELO) virus.

### Claim 6 (depends on 5)

The avidenoviral gene transfer vector of claim 5, wherein the avidenoviral genome partially deleted of the open reading frames 1, 15 and 2.

### Claim 7 (depends on 5)

The avidenoviral gene transfer vector of claim 5, wherein the open reading frames 1, 15 and 2 are partially replaced by heterologous transgenes.

### Claim 8

An aviadenoviral complimentary genome construct, wherein the open reading frames 1, 15 and 2 of the CELO genome are expressed.

### Claim 9 (depends on 9)

An aviadenoviral complimentary genome construct of claim 9, wherein the open reading frames 1, 15 and 2 are carried with a CELO genome fragment.

### Claim 10 (depends on 9)

An aviadenoviral complimentary genome construct of claim 9, wherein the open reading frames 1, 15 and 2 are expressed from a expression vector.

### Claim 11

A packaging and host cell for aviadenoviral vectors comprising an avian cell.

### Claim 12 (depends on 11)

A packaging and host cell of claim 11, wherein the cell has been transfected with a construct that expressed genes corresponding to the adenoviral E1A and E1B regions.

### Claim 13 (depends on 11)

A packaging and host cell of claim 11, wherein the cell has been transfected with a construct that encompassed the CELO open reading frames 22 and 8.

### Claim 14

A replication and encapsidation scheme for a replication-deficient aviadenoviral vector comprising:
(1) a replication-deficient aviadenoviral vector;
(2) a complimentary aviadenoviral construct;
(3) an avian packaging or host cell; and
(4) co-transfection of a replication-deficient aviadenoviral vector and a complimentary aviadenoviral construct into the avian packaging or host cell.

### Claim 15

An aviadenoviral packaging expression vector, comprising a CELO aviadenovirus derived genome deleted of the packaging signal Ψ.

### Claim 16 (depends on 15)

An aviadenoviral packing expression vector of claim 15, wherein its genome is deleted of at least one of its ITRs.

### Claim 17 (depends on 15)

An aviadenoviral packaging expression vector of claim 15, wherein its genome is functionally deleted of the open reading frames 9, 10 and 11.

### Claim 18

A replication and encapsidation scheme for fully deleted “gutted” aviadenoviral vector comprising:
(1) a fully deleted “gutted” aviadenoviral vector;
(2) an aviadenoviral packaging expression vector construct;
(3) an avian packaging or host cell; and
(4) co-transfection of a fully deleted “gutted” aviadenoviral vector and an aviadenoviral packaging expression vector construct into the avian packaging or host cell.

### Claim 19 (depends on 14)

An encapsidated replication-deficient aviadenoviral vector of claim 14, wherein the vector is used as a gene transfer vector.

### Claim 20 (depends on 14)

An encapsidated replication-deficient aviadenoviral vector of claim 14, wherein the vector is used for vaccination.

### Claim 21 (depends on 18)

An encapsidated replication-deficient aviadenoviral vector of claim 18, wherein the vector is used as a gene transfer vector.

### Claim 22 (depends on 18)

An encapsidated replication-deficient aviadenoviral vector of claim 18, wherein the vector is used for vaccination.
